In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting ...

After a delay, the FDA has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately ...

The patient panels of physicians underrepresented in medicine (URiM) showed that they had greater odds of being a Medicaid ...

Novo Nordisk said it’s open to discussions with PBMs based on their commitments that a lower semgalutide list price would not ...

Neither party wants to be perceived as threatening Medicare. The Biden administration has taken steps to reduce payment to ...

Results looking at the first season of RSV use shows that it is 75% effective at preventing RSV-associated hospitalizations ...

A study found omitting a course of antibiotic prophylaxis was non-inferior to the routinely administering antibiotics in ...

Employment satisfaction, sleep quality and lack of physical movement were all tied to vitality levels, survey results show.

The Phase I/II trials for rare forms of hereditary blindness further confirmed the potential for gene therapy treatments of ...

Respondents predict that the highest rates will be reflected in all outpatient prescription drugs with an 11.4% increase, up ...

KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually.

Gilead Sciences is issuing a voluntary recall of one lot of Veklury (remdesivir) for Injection 100 mg/vial because of glass ...